Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Common antifungal drug shows promise against esophageal cancer

NCT ID NCT05563766

First seen Nov 05, 2025 · Last updated Jun 23, 2026 · Updated 28 times

Summary

This phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo surgery. The main goal is to see if more tumors completely disappear by the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Durham VA Medical Center, Durham, NC

    RECRUITING

    Durham, North Carolina, 27705-3875, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Michael E. DeBakey VA Medical Center, Houston, TX

    RECRUITING

    Houston, Texas, 77030-4211, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    RECRUITING

    Ann Arbor, Michigan, 48105-2303, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

    RECRUITING

    Dallas, Texas, 75216-7167, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Palo Alto Health Care System, Palo Alto, CA

    RECRUITING

    Palo Alto, California, 94304-1207, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Portland Health Care System, Portland, OR

    RECRUITING

    Portland, Oregon, 97207-2964, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    RECRUITING

    Seattle, Washington, 98108-1532, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Itraconazole (an antifungal drug)

What this could lead to

If it works, this could point toward a new way to boost the effectiveness of standard chemoradiation for esophageal cancer, potentially improving survival chances.

What could go wrong

This is a small, early-phase trial (78 people). The drug may not improve response rates as hoped, and side effects from adding itraconazole to chemoradiation are not yet fully known.

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma esophageal squamous cell carcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.